Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. It engages in the research, manufacture, and commercialization of medicines to treat nephropathic cystinosis, non-alcoholic steatohepatitis (NASH), Huntington's disease (HD), and aldehyde dehydrogenase deficiency (ALDH2). Its lead compound includes RP103, a capsule containing enteric coated micro-beads of cysteamine bitartrate that has completed Phase 3 trial for the treatment of cystinosis, is in Phase 2/3 trial for treating HD, and is in Phase 2b trial for the treatment of NASH. The company' clinical development pipeline comprises RP104, an enteric coated tablet formulation of cysteamine bitartrate that has completed Phase 2 trail; and Convivia, a Phase 2 product candidate for the management of acetaldehyde toxicity due to ALDH2 deficiency. Its preclinical product candidates include HepTide for the treatment of primary liver cancer and other liver diseases; NeuroTrans to deliver therapeutics across the blood-brain barrier; and WntTide for the treatment of breast cancer. Raptor Pharmaceuticals Corp. is headquartered in Novato, California.
2 months later
Address
Suite 200, 9 Commercial Blvd
NOVATO, CA 94949
United States
Key stats and ratios
|
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -93.77% | - |
| Return on average equity | -296.70% | - |
| Employees | 41 |
Raptor Pharmaceuticals Pipeline
No comments:
Post a Comment